The slow seep of software into the running of clinical trials has accelerated in recent years as its reliability has been proven by pioneers and everyone has become increasingly desperate to boost productivity. After this period of growth, the eClinical market is on the cusp of becoming a $5 billion sector.
In a new stab at improving online searches for clinical trials, a nonprofit effort has brought the world an open-source site called MyClinicalTrialLocator.com. The website was designed to make searches easier for patients and serve as a resource to the global research community.
Like a good tech partner should, NextDocs has stuck close to Microsoft and its software platforms for years.
BioClinica told investors that it won't be issuing annual guidance for 2013. That's because the provider of clinical trials software and core lab imaging is being bought in a $123 million private equity deal.
INC Research has signed on to use goBalto's web-based software to boost the process of getting clinical trials up and running, providing the Bay Area startup with what appears to be one of its biggest customer wins yet for the tech.
As drug developers seek efficient ways to study new treatments for complex disease, Pharmaceutical Product Development has tapped adaptive clinical trials software from technology consultancies Tessella and Berry Consultants.
Nextrials has found a new partner to adopt its clinical trials software, which is tailored for the iPad. InClin, a clinical research organization, plans to use Nextrials' Prism software to speed the start of trials and push down costs of drug development.
Medidata Solutions ($MDSO) has hit a milestone in use of its clinical trials software. Kaketsuken, a vaccine maker, has become the first pharma in Japan to use certain combined capabilities of Medidata's software products, the New York-based software company said Monday.
After their stints at Google, Nat Turner and Zach Weinberg have returned to their startup roots at Flatiron Health. The New York City startup emerged in recent months to heal healthcare woes with new software, and one area of interest on the group's radar is clinical trials.
AstraZeneca ($AZN) has plenty to learn from clinical trials that ended in failure, and the company has turned to many different new computer technologies to streamline its R&D efforts and boost efficiency in drug development. A company executive talks about these efforts in a wide-ranging interview with Bio-IT World.